Years of Know-
How
Advancing
Bacterial Therapeutics

Years of Know-
How Advancing
Bacterial Therapeutics

Our Services

List Labs is one of the most experienced CDMOs for bacterially-based products, with years of expertise supporting clients, including innovators developing LBPs and bacterial derived products for the microbiome therapeutics and biopharmaceutical markets.

We offer a full range of
services from early-stage

We offer a full range of services from early-stage process development to cGMP manufacturing for Phase I & II clinical supply, meeting the needs of pharmaceutical companies, biotechs, start-ups, and government organizations. Our expertise includes development and manufacturing of bacterial derived products from purified polysaccharides and proteins to live bacteria.

We are also currently planning our expansion to add Phase III and commercial manufacturing at a new facility, which will enhance our fully integrated CDMO offering.

Great stories
from great customers

“We are pleased to be partnering with List Labs in the manufacturing of our proprietary interferon alpha 2b. We believe our novel engineered interferon alpha 2b derived from our proprietary master cell bank offers important advantages that allows for a quick scale up of manufacturing, especially in terms of logistics and cost of goods,..

Dr. Doroudian, Altum Pharma

“List labs staff are scientifically sound and very responsive to needs during difficult times, especially during GMP manufacturing.”

Microbiome Therapeutic Company in Phase I Clinical Trials

“We are pleased to be partnering with List Labs in the manufacturing of our proprietary interferon alpha 2b. We believe our novel engineered interferon alpha 2b derived from our proprietary master cell bank offers important advantages that allows for a quick scale up of manufacturing, especially in terms of logistics and cost of goods,..

Dr. Doroudian, Altum Pharma

“List labs staff are scientifically sound and very responsive to needs during difficult times, especially during GMP manufacturing.”

Microbiome Therapeutic Company in Phase I Clinical Trials